Tokumasu Kazuki, Fujita-Yamashita Manami, Sunada Naruhiko, Sakurada Yasue, Yamamoto Koichiro, Nakano Yasuhiro, Matsuda Yui, Otsuka Yuki, Hasegawa Toru, Hagiya Hideharu, Honda Hiroyuki, Otsuka Fumio
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan.
Department of Infectious Diseases, Okayama University Hospital, Okayama 700-8558, Japan.
Vaccines (Basel). 2023 Oct 30;11(11):1661. doi: 10.3390/vaccines11111661.
Although many adverse reactions after SARS-CoV-2 vaccination have been reported, there have been few comprehensive studies on persistent symptoms after SARS-CoV-2 vaccination. The aim of this study was to determine the clinical characteristics of patients with various persistent symptoms after SARS-CoV-2 vaccination. A retrospective descriptive study was performed for patients who visited a specialized clinic established at Okayama University Hospital to evaluate adverse events after SARS-CoV-2 vaccination during the period from April 2021 to March 2023. Descriptive analysis was performed for 121 of 127 patients who visited the clinic during the study period, and separate analysis was performed for the other 6 patients who had serious complications, who required treatment with prednisolone, and who had persistent symptoms. The median [interquartile range] age of the patients was 48 years [31-64 years], and the patients included 44 males (36.4%) and 77 females (63.6%). The most frequent symptoms were sensory impairment (34 patients, 28.1%), general fatigue (30 patients, 24.8%), fever/low-grade fever (21 patients, 17.4%), and headache (21 patients, 17.4%). Serious complications included myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), sarcoidosis, aseptic meningitis, neuromyelitis optica spectrum disorders (NMOSDs), tendon adhesions, and idiopathic thrombocytopenia. Although causal relationships were not determined, 15 persistent symptoms after SARS-CoV-2 vaccination were characterized. All of the symptoms had onset from 12 hours to one week after vaccination, with 10 symptoms persisting for 6 months or longer. The most frequent symptom was sensory impairment.
尽管已经报告了许多新型冠状病毒2疫苗接种后的不良反应，但针对新型冠状病毒2疫苗接种后持续症状的综合研究却很少。本研究的目的是确定新型冠状病毒2疫苗接种后出现各种持续症状的患者的临床特征。对2021年4月至2023年3月期间前往冈山大学医院设立的专门诊所评估新型冠状病毒2疫苗接种后不良事件的患者进行了回顾性描述性研究。对研究期间就诊的127例患者中的121例进行了描述性分析，对另外6例有严重并发症、需要使用泼尼松龙治疗且有持续症状的患者进行了单独分析。患者的年龄中位数[四分位间距]为48岁[31 - 64岁]，其中男性44例(36.4%)，女性77例(63.6%)。最常见的症状是感觉障碍(34例，28.1%)、全身疲劳(30例，24.8%)、发热/低热(21例，17.4%)和头痛(21例，17.4%)。严重并发症包括肌痛性脑脊髓炎/慢性疲劳综合征(ME/CFS)、结节病、无菌性脑膜炎、视神经脊髓炎谱系障碍(NMOSDs)、肌腱粘连和特发性血小板减少症。虽然未确定因果关系，但对新型冠状病毒2疫苗接种后的15种持续症状进行了特征描述。所有症状均在接种后12小时至1周内出现，其中10种症状持续6个月或更长时间。最常见的症状是感觉障碍。
